Who are Symlin®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symlin, Cibacalcin, Symlin (pramlintide), pramlintide acetate (Symlin), Pramlintide + Insulin, Placebo cagrilintide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/symlin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Symlin® — Competitive Intelligence Brief

Symlin® (Symlin®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amylin analog. Area: Diabetes.

marketed Amylin analog Amylin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Symlin® (Symlin®) — Adocia. Symlin (pramlintide) is an amylin analog that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial blood glucose excursions in diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Symlin® TARGET	Symlin®	Adocia	marketed	Amylin analog	Amylin receptor
Symlin	PRAMLINTIDE	Astrazeneca Ab	marketed		Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3	2005-01-01
Cibacalcin	CALCITONIN HUMAN	Novartis	marketed	calcitonin (human synthetic)	Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1	1986-01-01
Symlin (pramlintide)	Symlin (pramlintide)	Baylor College of Medicine	marketed	Amylin analog	Amylin receptor
pramlintide acetate (Symlin)	pramlintide acetate (Symlin)	AstraZeneca	marketed	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3)
Pramlintide + Insulin	Pramlintide + Insulin	Montefiore Medical Center	marketed	Amylin analog + Insulin combination	Amylin receptor (pramlintide component); Insulin receptor (insulin component)
Placebo cagrilintide	Placebo cagrilintide	Novo Nordisk A/S	phase 3	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amylin analog class)

Adocia · 1 drug in this class
Baylor College of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Symlin® — Competitive Intelligence Brief. https://druglandscape.com/ci/symlin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab